telos rx GLP-1 Review (2026): Pricing, Coverage, and Tradeoffs

Item: telos rx
Author: RangeYourself

telos rx review. We publish no price for telos rx: the figures it advertises conflict across its own pages and rest on a basis it does not publish. One integrated care team across GLP-1, hormones/longevity, sexual health, and recovery (peptide-led telehealth) rather than a single-indication weight-loss pure-play. Independent 2026 review from RangeYourself.

By RangeYourselfLast verified 2026-07-17

Quick take

telos rx is compounded semaglutide and tirzepatide (injectable, plus needle-free oral/sublingual and a microdosed tirzepatide) inside an integrated peptide-led telehealth menu; medical services by an independent us-licensed medical group (arora health group), priced as cash-pay subscription with 'first month low as' intro pricing per medication; the ongoing recurring rate is not published on the public site (funnel-gated at start.telosrx.com), no single defensible recurring price (oak/liv body mechanism). Best for: One integrated care team across GLP-1, hormones/longevity, sexual health, and recovery (peptide-led telehealth) rather than a single-indication weight-loss pure-play. Watch out for: telos publishes only 'first month low as' intro figures (semaglutide $49, tirzepatide $99, oral tirzepatide $49, microdosed tirzepatide $69); the ongoing monthly rate is not shown on the public site and is confirmed inside the intake flow, confirm the real recurring price at enrollment. State availability is not published, no dispensing pharmacy is named, and shipped compounded medication is non-refundable.

Pricing summary

Price surface last checked: 2026-07-17 (we read the provider’s own pricing pages on this date and found no figure we could stand behind)
All-in monthly cost: No single defensible price, see the pricing notes
Semaglutide: Compounded, advertised 'first month low as $49'; ongoing recurring rate not published (funnel-gated), confirm at enrollment
Tirzepatide: Compounded, injectable advertised 'first month low as $99'; oral 'first month low as $49'; microdosed 'first month low as $69'; ongoing recurring rate not published, confirm at enrollment
Compounded vs brand-name: Compounded only
Insurance accepted: No insurance-billing path published (cash-pay); confirm at signup
Consult type: Async questionnaire, per the provider’s published flow
Dose-escalation pricing: Not published. telos shows only 'first month low as' intro figures per medication ($49 sema / $99 tirz / $49 oral tirz / $69 microdosed); the ongoing recurring rate and dose-tier pricing are gated inside the intake flow (start.telosrx.com), confirm at enrollment.
Refund policy: 100% refund if the clinician determines you don't qualify (no medication ships); shipped compounded medication is non-refundable (federal compounding restriction); subscription cancellable anytime in one click; multi-month plans re-price to the shortest covering plan on early cancellation ('Once paid, fees are non-refundable except as required by applicable law').
States served: Available in select states, confirm your state at signup

Check telos rx pricing →

Choose telos rx if

You want one integrated care team across GLP-1 weight loss, longevity/energy (NAD+), recovery (sermorelin), and sexual health (PT-141) rather than a single-indication program
You value an upfront 'compounded / not FDA-approved' disclosure and a LegitScript-certified telehealth platform
You're comfortable confirming the real ongoing monthly price at enrollment (telos publishes only 'first month low as' intro figures)
You want async care with a 5-minute online visit and a 100% refund if a clinician decides a GLP-1 isn't the right fit

Skip telos rx if

You want a single clearly-listed recurring price up front, a published state list, a named 503A/503B dispensing pharmacy, insurance billing, or a brand-name (non-compounded) GLP-1.

Contraindications and clinical notes

Standard GLP-1 contraindications per GLP-1 prescribing information (personal/family history of MTC or MEN 2); 'Prescriptions are never automatic or guaranteed', prescribing decisions rest with the independent US-licensed medical group.. Talk to a clinician about personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, or other conditions before starting any GLP-1 medication.

Verified programs with a published all-in monthly price

telos rx’s price on file has not passed our current verification cycle, so it is not compared here. The programs below carry a verified all-in monthly price, checked on each provider’s own pricing page and ranked lowest first as of September 3, 2026.

1.Embody
$69/mo (limited-time promo), verified August 21, 2026
See pricing →
2.Strut Health
$99/mo (sublingual/oral starting price), verified August 21, 2026
See pricing →
3.Trimi
$99/mo (annual-plan rate), verified August 21, 2026
See pricing →
4.HealthRX
$99/mo (12-month plan rate), verified August 21, 2026
See pricing →
5.bmiMD
$119/mo (12-month plan rate), verified September 3, 2026
See pricing →

Prices are each provider’s own published all-in monthly figure at the plan term shown, verified on the date listed. RangeYourself may earn a commission from some programs; that can only break an exact tie between verified equals and never changes the price order.

How telos rx compares

Frequently asked questions

How much does telos rx cost per month?

telos rx advertises figures, but we publish none of them as its price: they conflict across its own pages and/or rest on a plan basis it does not disclose, so there is no single defensible ongoing rate to quote. The figures it does advertise, and what each one actually rests on, are set out in full below. Not published. telos shows only 'first month low as' intro figures per medication ($49 sema / $99 tirz / $49 oral tirz / $69 microdosed); the ongoing recurring rate and dose-tier pricing are gated inside the intake flow (start.telosrx.com), confirm at enrollment.

Does telos rx accept insurance?

telos rx publishes cash-pay prices and we found no insurance-billing path on its own site. Where a provider's own FAQ leaves the door open, the answer sits inside its intake flow, which we do not enter, so confirm at signup rather than treating this as settled. If you want insurance-billed brand-name GLP-1, see our list of GLP-1 programs that accept insurance.

What states does telos rx serve?

telos rx serves Available in select states, confirm your state at signup.

Is telos rx compounded or brand-name?

telos rx prescribes compounded semaglutide and tirzepatide via state-licensed 503A pharmacies or 503B outsourcing facilities. Compounded medication is not individually FDA-approved. The shortage-era compounding pathway ended after the FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so compounding now proceeds under the ordinary rules for individual patients.

What's the catch with telos rx?

telos publishes only 'first month low as' intro figures (semaglutide $49, tirzepatide $99, oral tirzepatide $49, microdosed tirzepatide $69); the ongoing monthly rate is not shown on the public site and is confirmed inside the intake flow, confirm the real recurring price at enrollment. State availability is not published, no dispensing pharmacy is named, and shipped compounded medication is non-refundable. Avoid if: you want a single clearly-listed recurring price up front, a published state list, a named 503a/503b dispensing pharmacy, insurance billing, or a brand-name (non-compounded) glp-1.

What the records show

telos rx's Trustpilot record rests on a handful of reviews, directional at best, not statistically meaningful, and we found no BBB listing to supplement it.

Trustpilot: 4.3★ (7 reviews), small sample via Trustpilot, checked 2026-07-24

Very small review sample (7), directional only, not statistically representative.

Independently observed third-party data, not our own editorial score. Full methodology: GLP-1 Provider Reliability Report.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

About these products

These are compounded preparations, not FDA-approved for anti-aging or longevity indications, and a prescription from a licensed clinician is required. Compounding pharmacies are not individually reviewed by the FDA for the safety or effectiveness of a specific compounded product. We rank and describe these programs on price and access only, never on efficacy, outcomes, or benefit claims, and we do not repeat a provider’s own marketing claims as independently verified fact.

NAD+: NAD+ is not an FDA-approved drug, and its compounding status is not settled in its favor. In a warning letter to GenoGenix LLC dated January 20, 2026 (WL#718739), the FDA stated that NAD+ is not eligible for compounding by a 503B outsourcing facility. We could not identify a clear 503A pathway for it either: it has no USP monograph and is not a component of an approved drug. A Class I recall of an NAD+ injectable over endotoxin contamination is also on the record. We rank the programs on this page on published price only, and price is not a safety, quality, or eligibility signal here, confirm sourcing, the dispensing pharmacy, and any state restrictions directly with the provider before purchase, and discuss it with a prescribing clinician.

Sermorelin: not currently marketed as an FDA-approved product; it is compounded by licensed pharmacies for individual patients.

These peptide and longevity products are not identical to, and are never described here as generic or equivalent to, any FDA-approved drug, and unlike compounded GLP-1 medication most of them have no FDA-approved counterpart at all. State availability varies by provider and by product, several programs listed here disclose per-state restrictions; confirm eligibility in your state before purchase. RangeYourself does not provide medical advice and does not guarantee a prescription.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. We publish no price for telos rx: we read its own pricing pages on 2026-07-17 and found no single figure we could stand behind. Confirm the rate directly with the provider.